Stock Screener App

Frei -

Installieren

4.2873

1.17% 0.0473

Aquestive Therapeutics Inc (AQST)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism - Investing News Network

AQST Investors Have Opportunity to Lead Aquestive Therapeutics, I - The National Law Review

2026-07-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire

AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill

Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

SEC Form S-3 filed by Aquestive Therapeutics Inc. - Quantisnow

Form S-3 Aquestive Therapeutics Inc For: 26 June By Investing.com - Investing.com India

Aquestive Therapeutics | S-3: Registration statement for specified transactions by certain issuers - Moomoo

AQST Stock Price and Chart — NASDAQ:AQST - TradingView

Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Aquestive Therapeutics, Inc. Actuals & Estimates (NASDAQ:AQST) - TradingView

symbol__ Stock Quote Price and Forecast - CNN

AQST Forecast — Price Target — Prediction for 2027 - TradingView

LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9 - Moomoo

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review

Aquestive Therapeutics Inc (AQST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Aquestive Therapeutics director Julie Krop sells $125k in stock By Investing.com - Investing.com Nigeria

Form 4 Aquestive Therapeutics Inc For: 24 June By Investing.com - Investing.com Australia

Aquestive Therapeutics director Julie Krop sells $125k in stock - Investing.com

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? - Yahoo Finance

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Reach Out - ACCESS Newswire

Form 144 Aquestive Therapeutics For: 23 June By Investing.com - Investing.com Australia

Aquestive Therapeutics (AQST) reports Q1 loss, beats revenue estimates - MSN

2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Reach Out | NDAQ:AQST | Press Release - Stockhouse

Does US manufacturing give drugmakers a speed edge? - Pharma Voice

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect - ACCESS Newswire

AQUESTIVE THERAPEUTICS INC (AQST) Stock Chart - ChartMill

Aquestive Therapeutics (NYSE:AQST): What Insider Activity Reveals About Corporate Confidence - Kalkine Media

Have Aquestive Therapeutics Insiders Been Selling Stock? - simplywall.st

Aquestive Therapeutics Inc (AQST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Aquestive Therapeutics Inc (AQST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Aquestive Therapeutics Inc (AQST) Institutional Confidence - TradingKey

Aquestive Therapeutics Inc (AQST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aquestive Therapeutics Inc (AQST) Valuation: PE, PB & Fair Value Analysis - TradingKey

Aquestive Therapeutics Inc (AQST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Aquestive Therapeutics CEO sells $104,010 in company stock By Investing.com - Investing.com Canada

Aquestive Therapeutics CEO sells $104,010 in company stock - Investing.com UK

Insider Sell: Aquestive Therapeutics Inc (AQST) President and CE - GuruFocus

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

2026-06-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse

Aquestive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Krop Julie - Moomoo

Aquestive (AQST) awards Abigail Jenkins 50,500 stock options at $3.99 - Stock Titan

Aquestive Therapeutics (AQST) director receives 50,500 stock options grant - Stock Titan

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

AQST: FDA progress, global expansion, and all proposals passed with strong shareholder support - TradingView

ALKS

$54.74

0.71%

RDY

$14.65

2.05%

ELAN

$24.65

1.89%

NBIX

$175.34

0.86%

VTRS

$17.00

1.16%

UTHR

$559.10

2.19%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters